Effect of Different Doses of Interferon Beta-1a on MRI Outcomes in Multiple Sclerosis
Author Information
Author(s): Traboulsee A, AL-Sabbagh A, Bennett R, Chang P, Li DKB
Primary Institution: University of British Columbia
Hypothesis
Does IFN beta-1a, 44 mcg sc tiw, lead to greater reductions in T2 burden of disease compared to IFN beta-1a, 30 mcg im qw, in patients with relapsing-remitting multiple sclerosis?
Conclusion
Patients with relapsing-remitting multiple sclerosis treated with IFN beta-1a, 44 mcg sc tiw, had a greater reduction in T2 burden of disease after 48 weeks compared to those treated with IFN beta-1a, 30 mcg im qw.
Supporting Evidence
- Patients treated with IFN beta-1a, 44 mcg sc tiw, had a median percentage decrease in T2 burden of disease of -6.7%.
- The adjusted mean treatment difference in percentage change in burden of disease was -4.6% in favor of the higher dose.
- 67% of patients receiving IFN beta-1a, 44 mcg sc tiw, had stable or improved burden of disease compared to 53% in the lower dose group.
- Patients with neutralizing antibodies had a smaller reduction in burden of disease compared to those without.
Takeaway
This study found that a higher dose of interferon beta-1a helps people with multiple sclerosis have less disease visible on MRI scans after 48 weeks.
Methodology
A post-hoc analysis of MRI data from the EVIDENCE study, including patients with evaluable T2 MRI scans at baseline and week 48.
Potential Biases
Potential bias due to the open-label design and the presence of neutralizing antibodies affecting treatment outcomes.
Limitations
The study had a limited duration and a small number of patients with neutralizing antibodies, which may affect the generalizability of the results.
Participant Demographics
Patients were primarily white, with a mean age of 38.1 years, and included both men and women.
Statistical Information
P-Value
0.002
Statistical Significance
p = 0.002
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website